Physician profile
Michael Zoller
NPI 1912908278
$1,312.59
in general payments reported to CMS, 2019-2025
11 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2021: $45.46 · 2022: $115 · 2023: $236 · 2024: $219 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $380.98 | 2022-2025 | Dupixent |
| Genzyme Corporation | $301.04 | 2024-2025 | |
| Optinose US, INC. | $244.67 | 2019-2024 | |
| Acclarent, INC | $94.21 | 2019 | |
| Glaxosmithkline, LLC. | $72.13 | 2022-2025 | Nucala |
| Alk-Abello, INC | $71.43 | 2019-2022 | |
| Aerin Medical INC. | $56.29 | 2022-2025 | |
| Hikma Pharmaceuticals USA | $33.36 | 2023-2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $29.42 | 2025 | Neffy |
| Medtronic, INC. | $16.65 | 2025 | Propel |
| Phathom Pharmaceuticals, INC. | $12.41 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zoller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.